AnalystBook Research · Company Intelligence

CLOVER HEALTH INVESTMENTS, CORP. /DE

CLOVNasdaq

Built from CLOVER HEALTH INVESTMENTS, CORP. /DE's own SEC filings · updates as new filings land · sources cited throughout

or browse all covered companies

Clover Health grew revenue but losses and cash burn widened.

The read at a glance✓ Audited against SEC data
  • Business mixMedicare Advantage insurerNote
  • Revenue$1.92B, +40.3%OK
  • Net loss$85.5M, widerWatch
  • FCF($69.0M), worseWatch
  • Equity$308.7M, -9.5%Watch
  • Altman/Beneish/EQWeak Z; no M/EQWatch
  • Insiders3 purchases / 12 salesNote

Business

Clover Health is a Medicare Advantage insurer using the Clover Assistant platform within its care model.

Where the revenue comes from

Fiscal 2025, as CLOVER HEALTH INVESTMENTS, CORP. /DE reports it. History and quarterly detail are in the app.

  • Insurance Operations$1.9B

Leadership changes

From CLOVER HEALTH INVESTMENTS, CORP. /DE's own filings, the day they're filed.

  • Brady Priest · Chief Executive Officer · departureeff. 2026-07-03
  • Thomas L. Tran · Chairman · departureeff. 2025-06-10
  • Thomas L. Tran · director · appointmenteff. 2024-08-20

Latest filings

  • 8-K · Company announcement2026-08-20
  • 10-Q · Quarterly report2026-08-07
  • 8-K · Company announcement2026-08-05
  • 8-K · Company announcement2026-07-17
  • 8-K · Company announcement2026-06-18
In the full recordFree for 14 days
  • What changed🔒
  • Insider signal🔒
  • Growth quality🔒
  • Margins & accounting🔒
  • Capital allocation🔒
  • Real risks🔒
  • The long arc🔒
  • Company history🔒
  • Main tension🔒
  • The filings, readable — with what changed vs the prior year highlighted🔒
  • Full financial statements, industry-aware, sources cited throughout🔒
  • Forensic score history & components — the trend, not one year🔒
  • Ownership: insider buys/sells, clusters, activist stakes🔒
  • Ana — ask about CLOVER HEALTH INVESTMENTS, CORP. /DE, every answer cited to the official filings🔒

Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.

14-day free trial, no credit card. For research purposes only; not investment advice.